Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$13.72
-1.2%
$14.26
$10.46
$21.69
$4.91B0.54625,110 shs530,956 shs
Paragon 28, Inc. stock logo
FNA
Paragon 28
$13.11
+0.1%
$13.04
$4.65
$13.13
$1.10B1.471.08 million shs19.38 million shs
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
$158.97
+0.5%
$162.86
$123.00
$257.40
$4.73B1.39583,830 shs315,939 shs
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$73.26
-1.3%
$57.41
$36.93
$74.50
$3.36B-2.29737,909 shs776,359 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
0.00%+13.70%-8.38%-20.25%-7.92%
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.00%+0.08%+0.61%+12.68%+35.80%
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
0.00%+5.68%-1.14%-15.79%-32.18%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.00%+4.69%+8.71%+52.43%+86.22%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
3.8277 of 5 stars
4.12.00.00.02.40.03.8
Paragon 28, Inc. stock logo
FNA
Paragon 28
1.675 of 5 stars
1.25.00.00.02.63.30.6
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
4.7856 of 5 stars
4.43.00.04.82.22.51.9
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
4.6954 of 5 stars
4.61.00.04.64.13.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
2.25
Hold$18.8237.16% Upside
Paragon 28, Inc. stock logo
FNA
Paragon 28
2.33
Hold$14.208.36% Upside
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
2.70
Moderate Buy$218.9037.70% Upside
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3.20
Buy$104.6742.87% Upside

Current Analyst Ratings Breakdown

Latest FNA, INSP, BLCO, and SLNO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/24/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/24/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$93.00 ➝ $145.00
4/21/2025
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$190.00 ➝ $175.00
4/21/2025
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$234.00 ➝ $216.00
4/15/2025
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$260.00 ➝ $215.00
4/15/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
4/4/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$18.00 ➝ $17.00
4/3/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$17.00 ➝ $15.00
3/31/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$70.00 ➝ $100.00
3/28/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$70.00 ➝ $81.00
3/28/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$24.00 ➝ $15.00
(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$4.79B1.01$1.63 per share8.41$18.57 per share0.74
Paragon 28, Inc. stock logo
FNA
Paragon 28
$256.18M4.29N/AN/A$2.05 per share6.39
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
$802.80M5.89$1.52 per share104.41$23.25 per share6.84
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/A$5.16 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
-$317M-$0.91N/A14.290.85-6.62%3.35%1.66%4/30/2025 (Estimated)
Paragon 28, Inc. stock logo
FNA
Paragon 28
-$57.53M-$0.63N/AN/AN/A-25.31%-37.90%-18.22%5/14/2025 (Estimated)
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
$53.51M$1.7391.8949.372.866.67%8.19%7.09%5/5/2025 (Estimated)
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$38.99M-$4.26N/AN/AN/AN/A-61.99%-55.21%5/7/2025 (Estimated)

Latest FNA, INSP, BLCO, and SLNO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Paragon 28, Inc. stock logo
FNA
Paragon 28
-$0.19N/AN/AN/A$69.62 millionN/A
5/7/2025Q1 2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$1.08N/AN/AN/AN/AN/A
5/5/2025Q1 2025
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
-$0.23N/AN/AN/A$194.89 millionN/A
4/30/2025Q1 2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$0.06N/AN/AN/A$1.15 billionN/A
3/6/2025Q4 2024
Paragon 28, Inc. stock logo
FNA
Paragon 28
-$0.12-$0.13-$0.01-$0.13$70.81 million$71.75 million
3/5/2025Q4 2024
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$0.86-$1.27-$0.41-$1.27N/AN/A
2/19/2025Q4 2024
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$0.23$0.25+$0.02-$0.01$1.26 billion$1.28 billion
2/10/2025Q4 2024
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
$0.74$1.15+$0.41$1.15$239.76 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/A
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
N/AN/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
0.72
1.60
1.01
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.79
3.50
1.60
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
N/A
7.13
6.22
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/A
17.26
17.26

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
11.07%
Paragon 28, Inc. stock logo
FNA
Paragon 28
63.57%
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
94.91%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
97.42%

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
0.15%
Paragon 28, Inc. stock logo
FNA
Paragon 28
15.32%
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
4.10%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
12.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
12,500353.37 million351.94 millionOptionable
Paragon 28, Inc. stock logo
FNA
Paragon 28
343,00083.94 million70.89 millionOptionable
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
76029.76 million28.45 millionOptionable
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3045.86 million37.81 millionOptionable

Recent News About These Companies

Soleno Therapeutics price target raised to $145 from $93 at Piper Sandler
Piper Sandler Sticks to Its Buy Rating for Soleno Therapeutics (SLNO)
Soleno Therapeutics announces VYKAT XR launch
Soleno Therapeutics Announces VYKAT(TM) XR Launch

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$13.72 -0.17 (-1.22%)
Closing price 04/25/2025 03:59 PM Eastern
Extended Trading
$13.72 -0.01 (-0.04%)
As of 04/25/2025 04:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Paragon 28 stock logo

Paragon 28 NYSE:FNA

$13.10 +0.02 (+0.11%)
Closing price 04/17/2025
Extended Trading
$13.10 0.00 (0.00%)
As of 04/17/2025 05:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

Inspire Medical Systems stock logo

Inspire Medical Systems NYSE:INSP

$158.97 +0.77 (+0.49%)
Closing price 04/25/2025 03:59 PM Eastern
Extended Trading
$159.16 +0.19 (+0.12%)
As of 04/25/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

Soleno Therapeutics stock logo

Soleno Therapeutics NASDAQ:SLNO

$73.26 -0.97 (-1.31%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$73.28 +0.02 (+0.03%)
As of 04/25/2025 04:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.